Sharemaestro Newsreel

PODD's Q2 Earnings Top Estimates, FY'26 Sales View Cut, Stock Down

Insulet Corporation PODD reported second-quarter 2026 adjusted earnings per share (EPS) of $1.66, up 41.5% year over year. The bottom line beat the Zacks Consensus Estimate by 15.28%. GAAP EPS came in at $1.37 compared with the year-ago quarter's figure of 32 cents. Revenues …

Pfizer Rises Almost 7% Post Q2 Results: How to Play the Stock

Pfizer PFE stock has risen 6.9% since it announced second-quarter 2026 results on Aug. 4. Pfizer delivered a solid second quarter, beating estimates for both earnings and revenues. While earnings growth was flat year over year, revenues rose 1% on an operational basis. Strength …

BioMarin to Participate at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 8:00AM ET in Boston

SAN RAFAEL, Calif., Aug. 10, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced management will present at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 8:00AM ET in Boston.BioMarin Pharmaceutical logo An audio webcast of the presentation …

Bristol Myers Squibb Advances U.S. Manufacturing Investment with New $2.3 Billion Campus in Houston, Texas

New State-of-the-Art Facility Will Create Nearly 500 Skilled Jobs and Accelerate the Delivery of Next-Generation Medicines Investment Furthers BMS' $40 Billion Commitment to American Innovation, Manufacturing and Economic Growth PRINCETON, N.J., August 10, 2026--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE:BMY) today announced the selection of Houston, …

Weekly Roundup on the Cannabis Sector & Psychedelic Sector

Key Takeaways; Cannabis Sector Canopy Growth Posted 13% Revenue Growth as Losses Narrowed Sharply in Q1 FY2027 Aurora Cannabis Narrowed Q1 Loss as International Medical Cannabis Growth Gained Ground Cronos Group Reported Record Q2 Revenue as Profitability and EBITDA Surged Key Takeaways; Psychedelic Sector …

Can Johnson & Johnson (JNJ) Challenge Intuitive Surgical (ISRG) After Ottava’s FDA Approval?

Johnson & Johnson (NYSE:JNJ) has officially entered the U.S. soft-tissue robotic surgery market after receiving FDA De Novo authorization for its OTTAVA robotic surgical system. The authorization represents an important milestone for J&J's MedTech ambitions, but the company is entering a market in which …

Beat the Market Like Zacks: Aveanna, FactSet, Shopify in Focus

Last Friday, the three major Wall Street indexes closed a winning week. The Nasdaq Composite, the S&P 500 and the Dow Jones Industrial Average gained 5.2%, 3.6% and 3%, respectively. Wall Street's strong weekly performance was driven by renewed investor optimism over the U.S. …

3 Beaten-Down Healthcare Stocks to Buy in August

Quick Read LLY grew Q1 revenue 56% and won FDA approval for the first oral GLP-1 pill, yet still trades 6% off its 52-week high. Healthcare has trailed SPY's 8% YTD gain, but JNJ's 64-year dividend streak and 20x forward P/E keep it compelling …

OSCR Crosses Above Average Analyst Target

In recent trading, shares of Oscar Health Inc (Symbol: OSCR) have crossed above the average analyst 12-month target price of $7.54, changing hands for $7.85/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade …

ACCESS Announces Multi-Year Strategic Agreement to Bring Advanced Cardiac Electrophysiology Technologies to Ambulatory Surgery Centers

Agreement supports ACCESS-affiliated ASCs in adopting the CARTO™ System and its integrated portfolio of mapping, intracardiac imaging, radiofrequency ablation and pulsed field ablation technologies NEW YORK, August 10, 2026--(BUSINESS WIRE)--ACCESS, through its physician-led group purchasing organization, ACCESS GPO, today announced a multi-year preferred portfolio …

Storebrand Europe Index - announcement of prospectus

Storebrand Asset Management AS Lysaker, 10 August 2026 Storebrand hereby announces the Prospectus with Articles of Association Appendix to the Prospectus ("tillæg" relevant to Danish investors) for Storebrand Europe Index, an index aware equity fund. The fund has been accepted for listing at Nasdaq …

Nvidia, Eli Lilly, and Disney Show It’s Time to Back the Top Dogs

Investors are still skittish enough that they only want to buy proven winners, so backing the favorite is a smart strategy right now. Continue Reading

OSCR Q2 Deep Dive: Individual Market Growth and AI Investments Shape Outlook

OSCR Q2 Deep Dive: Individual Market Growth and AI Investments Shape Outlook Health insurance company Oscar Health (NYSE:OSCR) reported Q2 CY2026 results exceeding the market's revenue expectations , with sales up 70.4% year on year to $4.88 billion. Its non-GAAP profit of $1.10 per …

Vertex Pharmaceuticals (VRTX) Eleva Su Guía Y Vuelve A Poner La Valoración En Foco

Ozempic For $50 a Month? Amazon Pharmacy Rolls Out Cheap Weight-Loss Drugs for Medicare Patients

Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Amazon.com Inc.'s Amazon Pharmacy will offer eligible Medicare beneficiaries weight-loss drugs for $50 per month through a new federal program aimed at expanding access. The company announced …

Thermo Fisher (TMO) vs Danaher (DHR): Which Life Sciences Stock Looks Better Positioned?

Thermo Fisher Scientific Inc. (NYSE:TMO) and Danaher Corporation (NYSE:DHR) are two of the world's largest life sciences tools companies, making them natural competitors for investors looking to capitalize on a recovery in pharmaceutical and biotechnology research spending. Both companies delivered better-than-expected second-quarter results, but …

Is Medtronic (MDT) Becoming a Turnaround Story?

UBS upgraded Medtronic (NYSE:MDT) to a Buy from Neutral today, telling investors in a research note that a "turnaround" is underway at the company. The upgrade raises an important question for investors: Is Medtronic finally returning to sustainable growth after years of underperformance, or …

The 5 Most Interesting Analyst Questions From AbbVie’s Q2 Earnings Call

The 5 Most Interesting Analyst Questions From AbbVie's Q2 Earnings Call AbbVie's second quarter results reflected robust product performance but were met with cautious investor sentiment. Management credited double-digit sales growth to strong execution in core immunology therapies, especially SKYRIZI and RINVOQ, and notable …

HIMS Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages Hims & Hers Health, Inc. (NYSE: HIMS) Investors to Contact the Firm

RADNOR, Pa., Aug. 09, 2026 (GLOBE NEWSWIRE) -- Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, is investigating potential violations of the federal securities laws by Hims & Hers Health, Inc. (NYSE: HIMS) on behalf of investors who …

3 Stocks Under $50 with Open Questions

3 Stocks Under $50 with Open Questions Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However, investors should remain vigilant as some may still have unproven business models, leaving them vulnerable …

NOVARTIS AG Equity-to-Asset: 0.34 — 26% Below Median

UnitedHealth (UNH) Commits $4M to Tennessee Health Hub Expansion

On July 29, UnitedHealth Group (NYSE:UNH) announced a $4 million commitment, funded through the United Health Foundation, to expand the University of Tennessee Health Sciences' health hub network from 5 locations to 13 across the state by the end of 2027, a buildout expected …

Zoetis Q2 Earnings Call Highlights

Key Points Interested in Zoetis Inc.? Here are five stocks we like better. Zoetis reported mixed second-quarter results: Revenue was $2.5 billion, flat reported and down 1% organically, while adjusted EPS rose 4% to $1.87 due partly to share repurchases. Weak U.S. companion-animal demand …

Zimmer Biomet Q2 Earnings Call Highlights

Key Points Interested in Zimmer Biomet Holdings, Inc.? Here are five stocks we like better. Zimmer Biomet reported solid Q2 growth: Net sales rose 4.8% to $2.177 billion, driven by hips, specialty businesses and technology. Adjusted EPS was $2.07, while U.S. organic sales increased …

Bronstein, Gewirtz & Grossman LLC Urges Regeneron Pharmaceuticals, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

NEW YORK, Aug. 09, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and certain of its officers. This lawsuit seeks to recover …

How Investors Are Reacting To IQVIA Holdings (IQV) Cardiac Gene Therapy Push And Higher 2026 Revenue Outlook

In late July and early August 2026, IQVIA Holdings and Medera announced a collaboration pairing IQVIA's global clinical and commercialization infrastructure with Medera's Sardocor and Novoheart cardiac gene therapy and human-based drug discovery platforms, alongside IQVIA's second-quarter results, raised full-year 2026 revenue guidance to …

Johnson & Johnson Has Increased Its Dividend for 64 Consecutive Years. Here's How Much $10,000 Invested in the Dividend King Pays Annually.

Key Points Few companies have a longer track record of uninterrupted dividend growth. This streak is likely to be prolonged well into the foreseeable future. While still an income stock, Johnson & Johnson is also being priced somewhat like a growth stock.10 stocks we …

Notable healthcare headlines for the week: Eli Lilly, Novo Nordisk, and Pfizer in focus

Wall Street’s major market averages ended higher on Friday after July's nonfarm payrolls surprised to the downside, showing an unexpected contraction in employment. The blue-chip Dow edged up 0.3%, the benchmark S&P 500 gained 0.62%, and the tech-focused Nasdaq Composite jumped 1.3%. The S&P …

Earnings Week Ahead: SMCI, CSCO, JD, PLUG, and more

[Business Person Reviewing Quarterly Report During Meeting in Office Setting] The second full week of August features a diverse earnings slate spanning AI infrastructure, semiconductors, space technology, healthcare, financials, and consumer names, with Super Micro Computer (SMCI [https://seekingalpha.com/symbol/SMCI]), Nebius (NBIS [https://seekingalpha.com/symbol/NBIS]), Cisco Systems (CSCO …

There's a 58% Chance of a Fed Rate Hike in October. These Are Stocks to Buy Anyway.

Key Points UnitedHealth's comeback shouldn't be derailed by a potential rate hike. JPMorgan Chase's net investment income would increase with higher rates. Chevron's business would almost certainly be booming in an environment where rate hikes were needed.10 stocks we like better than UnitedHealth Group …

Las acciones de Becton Dickinson (BDX) siguen pareciendo baratas tras su subida del 19 %

Eli Lilly (LLY) Posts Blowout Growth And Raises Its Outlook

Eli Lilly (NYSE:LLY) delivered a quarter that forced Wall Street to catch up to its own numbers. On August 5, the company reported second-quarter revenue of $23.0 billion, up 48% from a year earlier, and used the momentum to raise its full-year sales and …

Johnson & Johnson (JNJ) Stock Looks Cheap On Cash Flow Yet Pricey On Earnings

Solventum (SOLV) Stock Fair Value Rises After Q2 And HIS Separation Plans

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Solventum's analyst fair value estimate has been revised from US$82.15 to US$93.15, a shift of about 13% in the updated framework. This adjustment …

UnitedHealth Group (UNH) Leans On Optum And Medicare Advantage, Is The Stock Already Pricey?

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. UnitedHealth Group (UNH) is back in focus after fresh attention on its Medicare Advantage and Optum Health businesses, which are helping offset pressure …

Becton Dickinson (BDX) Stock Sees Modest Fair Value Lift After Mixed Analyst Views

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Becton Dickinson has seen its analyst fair value estimate move from US$181.23 to US$189.58, signaling a refreshed price target framework that investors are watching …